Please Wait a Moment
X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

27 Jul, 2020 | Return|

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

FDA Guidance for Industry for Babesia

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2020

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >

National Blood Donor Month – January 2020

That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...

Read More >

CTS Tampa Implementation date change for Ultrio Elite

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...

Read More >

CTS St. Louis Implements New Laboratory Information System

On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...

Read More >

Updated Sample Acceptability Document

CTS was recently notified that one of the tubes listed in the Sample Acceptability document...

Read More >